DelveInsight’s “Dilated Cardiomyopathy Pipeline Insight 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Dilated Cardiomyopathy pipeline landscape. It covers the Dilated Cardiomyopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dilated Cardiomyopathy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Dilated Cardiomyopathy Pipeline @ https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight

Key Takeaways from the Dilated Cardiomyopathy Pipeline Report

• On June 15, 2026- Alexion Pharmaceuticals Inc. initiated a Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
• On June 03, 2026- Kardigan Inc. conducted a phase 2b/3 study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM).
• DelveInsight’s Dilated Cardiomyopathy pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Dilated Cardiomyopathy treatment.
• The leading Dilated Cardiomyopathy Companies such as Berlin Cures, AstraZeneca, Biohaven Pharmaceuticals, Tenaya Therapeutics and others.
• Promising Dilated Cardiomyopathy Therapies such as Carvedilol, Metoprolol succinate, ARRY-371797, Danicamtiv, Ifetroban, ALXN2350, and others.

Stay ahead with the most recent pipeline outlook for Dilated Cardiomyopathy @ Dilated Cardiomyopathy Treatment Drugs

The Dilated Cardiomyopathy Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Dilated Cardiomyopathy Pipeline Report also highlights the unmet needs with respect to the Dilated Cardiomyopathy.

Dilated Cardiomyopathy Overview

Dilated Cardiomyopathy (DCM) is a disorder characterized by dilation and impaired contraction of the left or both ventricles, leading to reduced cardiac output. It is one of the most common types of cardiomyopathy and a major cause of heart failure worldwide. DCM can be idiopathic, genetic, or secondary to factors such as viral infections, alcohol abuse, chemotherapy, or metabolic disorders. Patients with DCM often present with features of congestive heart failure. Common symptoms include progressive shortness of breath (dyspnea), fatigue, reduced exercise tolerance, and peripheral edema (swelling of legs and ankles). Some individuals may experience palpitations, syncope, or chest discomfort due to arrhythmias. In advanced cases, signs like jugular venous distension and pulmonary congestion may be evident.

Dilated Cardiomyopathy Emerging Drugs Profile

• Danicamtiv: Kardigan, Inc

Danicamtiv is an investigational cardiac myosin activator targeting familial and genetic dilated cardiomyopathy (DCM) driven by sarcomeric mutations to restore cardiac function through direct activation in both the left atrium and left ventricle. KINSHIP-DCM is planned to begin this year to evaluate the safety and efficacy of danicamtiv as a potential first-in-class treatment for familial and genetic DCM. Kardigan in-licensed exclusive worldwide development and commercialization rights to danicamtiv, an investigational drug discovered at MyoKardia and further developed by Bristol Myers Squibb. Currently the drug is in Phase II/III stage of development for the treatment of Dilated Cardiomyopathy.

• HS-005: Heartseed Inc

HS-005 (Heartseed Inc.) is an investigational regenerative cell therapy being developed by Heartseed Inc. for severe heart failure, including conditions such as dilated cardiomyopathy. It consists of allogeneic iPSC-derived cardiomyocyte spheroids designed to restore damaged heart muscle (cardiac remuscularization). The therapy is administered via a minimally invasive catheter-based delivery system, enabling precise injection of the cell spheroids into the myocardial wall, improving cell retention and viability compared to single-cell approaches. HS-005 is currently in Phase I/II clinical development (EMERALD study), evaluating its safety and efficacy in patients with advanced heart failure. Overall, HS-005 represents a next-generation cardiac regenerative approach aiming to restore contractile function rather than just manage symptoms, differentiating it from conventional heart failure therapies

Explore groundbreaking therapies and clinical trials in the Dilated Cardiomyopathy Pipeline @ New Dilated Cardiomyopathy Drugs

The Dilated Cardiomyopathy Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Dilated Cardiomyopathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dilated Cardiomyopathy Treatment.
• Dilated Cardiomyopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dilated Cardiomyopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dilated Cardiomyopathy market

Dilated Cardiomyopathy Companies

Berlin Cures, AstraZeneca, Biohaven Pharmaceuticals, Tenaya Therapeutics and others.

The Dilated Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Dilated Cardiomyopathy Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Dilated Cardiomyopathy Market Drivers and Barriers

Scope of the Dilated Cardiomyopathy Pipeline Report

• Coverage- Global
• Dilated Cardiomyopathy Companies- Berlin Cures, AstraZeneca, Biohaven Pharmaceuticals, Tenaya Therapeutics and others.
• Dilated Cardiomyopathy Therapies- Carvedilol, Metoprolol succinate, ARRY-371797, Danicamtiv, Ifetroban, ALXN2350, and others.
• Dilated Cardiomyopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dilated Cardiomyopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Dilated Cardiomyopathy Therapies and clinical trials @ Dilated Cardiomyopathy Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Dilated Cardiomyopathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dilated Cardiomyopathy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Emprumapimod: Pfizer
9. Mid Stage Products (Phase I/II)
10. Mesenchymal stem cell therapy: Longeveron
11. Early Stage Products (Phase I)
12. Preclinical Stage Products
13. CDR 426D: Cardior Pharmaceuticals
14. Inactive Products
15. Dilated Cardiomyopathy Key Companies
16. Dilated Cardiomyopathy Key Products
17. Dilated Cardiomyopathy- Unmet Needs
18. Dilated Cardiomyopathy- Market Drivers and Barriers
19. Dilated Cardiomyopathy- Future Perspectives and Conclusion
20. Dilated Cardiomyopathy Analyst Views
21. Dilated Cardiomyopathy Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/dilated-cardiomyopathy-pipeline-insight